TEM
New deal, same race to scale
Tempus AI is back in the spotlight after announcing it’s expanding its collaboration with Predicta Biosciences. The goal: push GenoPredicta, a co-branded whole-genome sequencing assay, into more hands for hematologic malignancies and measurable residual disease monitoring.
Why the market cared
This isn’t just science-fair trivia. Tempus says the assay can detect tumor cells at ultra-low levels — think roughly one in a million cells — using a combo of flow cytometry and whole-genome sequencing. That kind of sensitivity could make the test useful in lower-tumor-burden cases, which is basically Wall Street’s way of hearing: “bigger addressable market, please.”
Less biopsy, more workflow
Tempus also framed the collaboration as a way to simplify testing into a single workflow and potentially reduce the need for invasive bone marrow biopsies. If a blood test can spare patients from a more painful procedure, that’s not just a clinical win — it’s the kind of thing that can help a product get adopted faster.
The stock angle
TEM jumped about 10.8% on the news, which tells you investors are still very much in “show me the commercialization” mode. This kind of partnership matters because it can turn Tempus from a cool data-and-diagnostics story into a recurring revenue machine — or at least nudge it a little closer.
Big picture: Tempus keeps trying to prove that its genomics platform isn’t just smart, it’s scalable. And in biotech-land, scale is where the real money starts to show up.